OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases 24,463 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 32.5% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 99,632 shares of the company's stock after purchasing an additional 24,463 shares during the quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.14% of Kiniksa Pharmaceuticals worth $1,971,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in KNSA. Teacher Retirement System of Texas grew its position in shares of Kiniksa Pharmaceuticals by 7.1% in the 4th quarter. Teacher Retirement System of Texas now owns 10,862 shares of the company's stock valued at $215,000 after purchasing an additional 719 shares during the period. Martingale Asset Management L P boosted its stake in shares of Kiniksa Pharmaceuticals by 1.9% during the 4th quarter. Martingale Asset Management L P now owns 49,360 shares of the company's stock worth $976,000 after buying an additional 900 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its position in shares of Kiniksa Pharmaceuticals by 12.9% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,814 shares of the company's stock worth $174,000 after purchasing an additional 1,004 shares during the last quarter. Franklin Resources Inc. increased its holdings in Kiniksa Pharmaceuticals by 1.7% during the third quarter. Franklin Resources Inc. now owns 67,533 shares of the company's stock worth $1,798,000 after buying an additional 1,100 shares during the last quarter. Finally, MetLife Investment Management LLC lifted its stake in Kiniksa Pharmaceuticals by 6.3% in the 4th quarter. MetLife Investment Management LLC now owns 23,095 shares of the company's stock valued at $457,000 after purchasing an additional 1,374 shares during the last quarter. Institutional investors own 53.95% of the company's stock.

Wall Street Analyst Weigh In

Several analysts recently commented on the stock. Citigroup initiated coverage on shares of Kiniksa Pharmaceuticals in a report on Thursday, March 13th. They set a "buy" rating and a $40.00 target price for the company. Jefferies Financial Group boosted their price objective on Kiniksa Pharmaceuticals from $40.00 to $45.00 and gave the stock a "buy" rating in a report on Tuesday, April 29th. Finally, Wedbush reaffirmed an "outperform" rating and issued a $34.00 target price on shares of Kiniksa Pharmaceuticals in a research report on Wednesday, April 16th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus price target of $38.80.

Insider Activity

In related news, insider Ross Moat sold 18,259 shares of the business's stock in a transaction on Monday, April 21st. The stock was sold at an average price of $20.29, for a total transaction of $370,475.11. Following the sale, the insider now owns 9,415 shares in the company, valued at $191,030.35. The trade was a 65.98% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Mark Ragosa sold 36,372 shares of the stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $22.25, for a total value of $809,277.00. Following the completion of the transaction, the chief financial officer now owns 22,958 shares of the company's stock, valued at $510,815.50. This represents a 61.30% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 228,768 shares of company stock worth $5,591,506. Corporate insiders own 54.57% of the company's stock.

Kiniksa Pharmaceuticals Trading Up 3.1%

NASDAQ KNSA opened at $26.84 on Tuesday. The firm's 50 day simple moving average is $22.51 and its 200 day simple moving average is $21.29. The firm has a market capitalization of $1.95 billion, a price-to-earnings ratio of -191.70 and a beta of 0.07. Kiniksa Pharmaceuticals, Ltd. has a 1 year low of $17.38 and a 1 year high of $28.56.

Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) last issued its quarterly earnings results on Tuesday, April 29th. The company reported $0.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.02 by $0.09. The company had revenue of $137.79 million for the quarter, compared to analyst estimates of $128.35 million. Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. The company's revenue for the quarter was up 72.5% compared to the same quarter last year. During the same quarter last year, the company posted ($0.25) EPS. On average, equities research analysts forecast that Kiniksa Pharmaceuticals, Ltd. will post -0.55 earnings per share for the current year.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.

Want to see what other hedge funds are holding KNSA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.